Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT8 | Q9H7Z6 | 5/20 | 0.46 |
| ▸ | BID | P55957 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.46 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | EP300 | Q09472 | 2/20 | 0.46 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.46 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | PLK1 | P53350 | 5/20 | 0.42 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | F7 | P08709 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27818384 | 0.94 | KAT8 (0.51) | KAT8BIDMCL1BCL2L1BAK1 | |
| SCHEMBL994989 | 0.81 | BID (0.43) | KAT8BIDMCL1BCL2L1BAK1 | |
| Diethylamine SCHEMBL27650052 | 0.80 | PLK1 (0.48) | KAT8BIDMCL1BCL2L1BAK1 | |
| SCHEMBL28106933 | 0.79 | KAT8 (0.41) | KAT8BIDMCL1BCL2L1BAK1 | |
| Diethylamine SCHEMBL27776404 | 0.79 | BID (0.67) | KAT8BIDMCL1BCL2L1BAK1 | |
| SCHEMBL995527 | 0.78 | BID (0.43) | KAT8BIDMCL1BCL2L1BAK1 | |
| SCHEMBL39503 | 0.77 | KAT8 (0.44) | KAT8BIDMCL1BCL2L1BAK1 | |
| SCHEMBL630807 | 0.77 | PLK1 (0.45) | KAT8BIDMCL1BCL2L1BAK1 | |
| SCHEMBL27756644 | 0.77 | AKR1C3 (0.50) | KAT8BIDMCL1BCL2L1BAK1 | |
| SCHEMBL5317590 | 0.76 | KAT8 (0.60) | KAT8BIDMCL1BCL2L1BAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720512-B1 | PHOTOSTABILIZATION OF A SUNSCREEN COMPOSITION WITH A COMBINATION OF AN ALPHA-CYANO-ß,ß-DIPHENYLACRYLATE COMPOUND AND A DIALKYL NAPHTHANATE | HALLSTAR INNOVATIONS CORP (US) | 2010-01-20 | — | — | EP | claimed |
| EP-2498772-B1 | COMPOSITION AND METHODS FOR IMPROVING SKIN APPEARANCE | SYTHEON LTD (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-119523833-A | Collagen microsphere ergothioneine compound, multifunctional high-efficiency broad-spectrum sun-screening composition containing compound and preparation method | 南京天纵易康生物科技股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-11903990-B2 | Compositions and methods for treating and removing seborrheic keratoses | STOECKER WILLIAM VAN DOVER (US) | 2024-02-20 | — | — | US | disclosed |
| EP-2533753-B1 | SUNSCREEN COMPOSITIONS COMPRISING UNIFORM, RIGID, SPHERICAL, NANOPOROUS CALCIUM PHOSPHATE PARTICLES, AND METHODS OF MAKING AND USING THE SAME | LABORATORY SKIN CARE INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220133828-A1 | Compositions and Methods for Treating and Removing Seborrheic Keratoses | STOECKER WILLIAM VAN DOVER (US) | 2022-05-05 | — | — | US | disclosed |
| CN-101203600-B | Methods and means for protecting the skin against pathogenic microorganisms | ORGANOBALANCE GMBH | 2015-05-13 | — | — | CN | disclosed |
| CN-101203600-A | Methods and means for protecting the skin against pathogenic microorganisms | ORGANOBALANCE GMBH (DE) | 2008-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133828-A1 | Compositions and Methods for Treating and Removing Seborrheic Keratoses | CAT, CUTA, GPX1 | KAT8 236/4885BID 3974/4885MCL1 1665/4885 |
| US-11903990-B2 | Compositions and methods for treating and removing seborrheic keratoses | CAT, CUTA, GPX1 | KAT8 236/4885BID 3974/4885MCL1 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.